Team:UC Davis/Project
From 2011.igem.org
(Difference between revisions)
Aheuckroth (Talk | contribs) |
Aheuckroth (Talk | contribs) |
||
Line 21: | Line 21: | ||
As of October 2011, we have a functioning mutant library generation and screening process, and a selection of well-characterized promoter mutants, including seven LacI promoter mutants and seven λ cI promoter mutants. We also have nine TetR promoter mutants and eight GFP mutants (two of which have been lovingly named "Orange-Mutated Green Fluorescent Protein," or "OMGfp" 1 and 2) which await further characterization. | As of October 2011, we have a functioning mutant library generation and screening process, and a selection of well-characterized promoter mutants, including seven LacI promoter mutants and seven λ cI promoter mutants. We also have nine TetR promoter mutants and eight GFP mutants (two of which have been lovingly named "Orange-Mutated Green Fluorescent Protein," or "OMGfp" 1 and 2) which await further characterization. | ||
+ | </div> | ||
</div> | </div> | ||
+ | <div class="floatboxleft"> | ||
+ | <h2>Project Selection</h2> | ||
+ | Why would we want to make mutants? What's so special about repressible promoters? Read about how we came to decide on this project idea <a href="https://2011.igem.org/Team:UC_Davis/Project_Selection">here.</a><br><br><br> | ||
+ | </div> | ||
+ | <div class="floatboxright"> | ||
+ | <h2>Process</h2> | ||
+ | Want to make your own mutant library? Curious as to how we assayed our promoter mutants, or how we selected variants that had well-spaced activity levels? Read about our library generation process <a href=""https://2011.igem.org/Team:UC_Davis/Process">here</a>. <br><br> | ||
</div> | </div> | ||
+ | |||
+ | <div class="floatboxleft"> | ||
+ | <h2>Notebook</h2> | ||
+ | The <a href="https://2011.igem.org/Team:UC_Davis/Notebook">notebook</a> page contains daily updates about our progress in lab, and also has a <a href="https://2011.igem.org/Team:UC_Davis/Gallery">gallery</a> where you can view pictures that we've taken in our lab.<br><br><br> | ||
+ | </div> | ||
+ | <br><br> | ||
+ | |||
+ | <div class="floatboxright"> | ||
+ | <h2>Attributions</h2> | ||
+ | Credit for the various facets of our project, from <a href="https://2011.igem.org/Team:UC_Davis/Attributions#Wet">wetlab work</a> to <a href="https://2011.igem.org/Team:UC_Davis/Attributions#Wiki">graphic design</a> can be found on our <a href="https://2011.igem.org/Team:UC_Davis/Attributions">attributions</a> page, along with a list of the <a href="https://2011.igem.org/Team:UC_Davis/Attributions#opensource">awesome, free, open-source software</a> that we used to make this project happen. | ||
<style> | <style> |
Revision as of 04:30, 28 September 2011
Start a Family
Got a favorite BioBrick? Check our our process for expanding basic parts into part families.Criteria
View our judging criteria for iGEM 2011 here.
Overview
We set out to develop a rugged process for the rapid production of mutant libraries of any BioBrick part using standard primers and a simple mutagenic PCR protocol. We chose to prototype this process by creating mutant libraries of the LacI, TetR and λ cI repressible promoters and to mutate GFP to visually assess our ability to create functional protein mutants.
As of October 2011, we have a functioning mutant library generation and screening process, and a selection of well-characterized promoter mutants, including seven LacI promoter mutants and seven λ cI promoter mutants. We also have nine TetR promoter mutants and eight GFP mutants (two of which have been lovingly named "Orange-Mutated Green Fluorescent Protein," or "OMGfp" 1 and 2) which await further characterization.
As of October 2011, we have a functioning mutant library generation and screening process, and a selection of well-characterized promoter mutants, including seven LacI promoter mutants and seven λ cI promoter mutants. We also have nine TetR promoter mutants and eight GFP mutants (two of which have been lovingly named "Orange-Mutated Green Fluorescent Protein," or "OMGfp" 1 and 2) which await further characterization.